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INTRODUCTION
This chapter addresses the management of BP in adults
with non–dialysis-dependent CKD who have received a
kidney transplant (CKD T). There is insufficient evidence
to make recommendations specific to children with a kidney
transplant.
5.1: We suggest that adult kidney transplant recipients
whose office BP is consistently 4130mmHg systolic
or 480mmHg diastolic be treated to maintain a
BP that is consistently r130mmHg systolic and
r80mmHg diastolic, irrespective of the level of
urine albumin excretion. (2D)
RATIONALE
In adult kidney transplant recipients we consider two
primary outcomes from the standpoint of BP: graft function
and CVD. High BP is well recognized as an important
risk factor for both decline in graft function and develop-
ment of CVD.153,284–288 Increased levels of both systolic
and diastolic BP are associated with worse graft survival over
a 7-year period after transplantation,289 and maintaining a
systolic BP o140 mm Hg at 3 years after transplantation is
associated with improved graft survival and reduced
cardiovascular mortality at 10 years.290 Similarly, high BP is
associated with an increased risk of graft loss and all-cause
mortality.291
Although no RCT defines BP targets in adult kidney
transplant recipients for clinically important end points
such as graft survival, cardiovascular events, or all-cause
mortality, our suggestion is that the BP target should not
deviate from the recommended target ofr130/80 mm Hg as
defined in the recent KDIGO Clinical Practice Guideline for
the Care of Kidney Transplant Recipients,292 since there have
been no recent data to contradict this recommendation.
Although the European Best Practice Guidelines for Renal
Transplantation 2002 recommended a target BP r125/
75 mm Hg in proteinuric patients, there is no evidence to
differentiate BP target based on albumin excretion in renal
transplant recipients.293 Because adult CKD T patients are at
high risk for both graft loss and development of CVD,284–288
we favor a target of r130/80 mm Hg rather than a target of
r140/90 mm Hg. We recognize that this recommendation is
based on observational data and have therefore given it a
grade of 2D.
5.2: In adult kidney transplant recipients, choose a BP-
lowering agent after taking into account the time
after transplantation, use of calcineurin inhibitors,
presence or absence of persistent albuminuria, and
other co-morbid conditions. (Not Graded)
RATIONALE
BP-lowering agents are prescribed in 70 to 90% of kidney
transplant recipients, according to both registry reports and
RCTs.294,295 There are many considerations in choosing anti-
hypertensive drugs for use in adult kidney transplant
recipients. These include side effects that are also seen in the
general population, side effects particular to kidney transplant
patients (e.g., increased propensity to hyperkalemia or anemia
with ACE-Is or ARBs), level of urine albumin, degree of
hemodynamic stability and the associated potential to alter
graft perfusion (especially in a period soon after transplanta-
tion), co-morbid conditions that may indicate or preclude
certain agents, interactions with immunosuppressive medica-
tions or other medications unique to patients with kidney
transplant patients, and long-term impact on graft function,
CVD, and all-cause mortality.296 Because of these considera-
tions and the absence of large trials with clinically important
outcomes, there is marked variability in the prescription of
cardioprotective medications after transplantation.294
Short-term RCTs (of duration r2 years) suggest a
beneficial effect of calcium-channel blockers, as compared
with either placebo or ACE-Is, with regard to level of kidney
function.297–300 In addition, a recent meta-analysis of RCTs
indicated that the use of calcium-channel blockers, versus
placebo or no treatment (plus additional agents in either
arm, as needed) was associated with a 25% lower rate of graft
loss (relative risk [RR] 0.75; 95% CI 0.57–0.99) and higher
GFR (by 4.5 ml/min; 95% CI 2.2–6.7).301 These findings
prompted the Canadian Society of Transplantation and
Canadian Society of Nephrology to question the recommen-
dation from the 2009 KDIGO Clinical Practice Guideline for
the Care of Kidney Transplant Recipients to use any class of
antihypertensive agent after kidney transplantation.292,302
Most transplantation centers prefer to use dihydropyridine
calcium-channel blockers for initial therapy after transplan-
tation, since these agents dilate afferent arterioles and
counteract the vasoconstrictive effect of CNIs298,303 (Supple-
mentary Tables 54–59 online). However, non-dihydropy-
ridines might interfere with the metabolism and excretion of
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the CNIs cyclosporine and tacrolimus, as well as the mTOR
inhibitors sirolimus and everolimus. When renal transplant
recipients are prescribed non-dihydropyridine calcium-
channel blockers, careful monitoring of CNIs and mTOR
inhibitors blood levels is required if drugs or dosages are
changed.
ACE-Is and ARBs are known to have acute hemodynamic
effects, resulting in an increase in SCr level, and are therefore
frequently avoided within the first 3 to 4 months after
transplantation, when acute rejection is a strong possibility,
and an increase in creatinine level can be difficult to
interpret.298,304,305 Side effects of ACE-Is and ARBs when
used soon after transplantation include increased creatinine
levels, hyperkalemia, and anemia. One study showed that
although 44% of patients were receiving ACE-Is or ARBs at
the time of transplantation, the proportion dropped to 12% at
1 month and subsequently increased to 24% at 6 months.294
In the longer term, especially in kidney-transplant patients
with persistent albuminuria, ARBs and ACE-Is should be
considered. Two analyses of registry data have been
published, with one showing a benefit and the other no
benefit with the use of ACE-Is or ARBs for graft and patient
survival.306,307 Small trials have examined various agents to
lower BP in kidney-transplant patients. One examined
losartan, captopril, and amlodipine and noted no change in
BP or kidney function between baseline and end of follow-up.
ACE-Is and ARBs did, however, reduce the risk of
proteinuria, as compared with a calcium-channel blocker308
(Supplementary Table 60 online).
The Study on Evaluation of Candesartan Cilexetil after
Renal Transplantation (SECRET) was an RCT of candesartan
versus placebo.309 The primary outcome was all-cause
mortality, cardiovascular morbidity, or graft failure. Enroll-
ment of 700 patients was planned, but unfortunately, the
study was terminated prematurely due to lower-than-
expected event rates after enrollment of 502 participants
because only 26 events took place in the 20 months of follow-
up (with no difference in frequency between the two arms),
whereas 210 events had been predicted over 3 years. Although
there was slightly better BP control in the active group versus
the control group (mean BP, 131/80 mm Hg vs. 137/
83 mm Hg, respectively), the relatively tight BP control in
both arms might have contributed to the low event rate. The
protein excretion rate decreased in the ARB arm and
increased in the placebo arm, but this difference may have
been influenced by the different achieved BP levels (Supple-
mentary Tables 61–62 online).
A large Canadian RCT of ramipril versus placebo is
ongoing.310 It will enroll 528 kidney-transplant patients who
underwent transplantation 46 months previously, have
protein excretion of 40.2 g per 24 hours, and have a GFR
20–55 ml/min/1.73 m2. Outcomes will include doubling of
SCr level, kidney failure, and death.
Because no large studies with clinically important out-
comes have been completed, we have chosen to follow the
recommendations of the KDIGO Clinical Practice Guideline
for the Care of Kidney Transplant Recipients292 and to provide
an ungraded statement.
RESEARCH RECOMMENDATIONS
RCTs are needed to determine:
K The optimal target BP for adult patients with kidney
transplants with a focus on clinically important outcomes
such as graft survival, CVD, and mortality.
K The effects of ACE-Is and ARBs versus placebo, ACE-Is
and ARBs versus calcium-channel blockers, and calcium-
channel blockers versus placebo regarding long-term graft
survival, CVD, and patient survival.
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